References
- American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society, 2016
- SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute, 2016. Available at: http://seer.cancer.gov/csr/1975_2013/[Last accessed 16 September 2016]
- NHPCO Facts and Figures: Hospice Care in America. Alexandria, VA: National Hospice and Palliative Care Organization, September 2015
- Taniyama TK, Hashimoto K, Katsumata N, et al. Can oncologists predict survival for patients with progressive disease after standard chemotherapies? Curr Oncol 2014;21:84
- McCarthy EP, Phillips RS, Zhong Z, et al. Dying with cancer: patients’ function, symptoms, and care preferences as death approaches. J Am Geriatr Soc 2000;48:S110-S21
- Hui D, Kim SH, Roquemore J, et al. Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients. Cancer 2014;120:1743-9
- Gwilliam B, Keeley V, Todd C, et al. Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ 2011;343:d4920
- Weeks JC, Cook EF, O’day SJ, et al. Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 1998;279:1709-14
- Gonsalves WI, Tashi T, Krishnamurthy J, et al. Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran’s Affairs cancer population. J Palliat Med 2011;14:1231-5
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med 2005;353:123-32
- Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non–small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR. 21 trial. J Thorac Oncol 2012;7:1653-60
- Grossi F, Rijavec E, Genova C, et al. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. Br J Canc 2017;116:36-43
- Gautschi O, Dingemans AM, Crowe S, et al. VeriStrat has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Canc 2013;79:59-64
- Goss G, Lee KH, Felip E, et al. Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung. Ann Oncol 2016;27(Suppl6):1238P
- Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non–small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Canc Inst 2007;99:838-46
- Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol 2012;7:40-8
- Kuiper JL, Lind JS, Groen HJ, et al. VeriStrat has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Canc 2012;107:1820-5
- Gregorc V, Novello S, Lazzari C, et al. Value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014;15:713-21
- Akerley WL, Nelson RE, Cowie RH, et al. The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Curr Med Res Opin 2013;29:517-25